Determining transition probabilities from mortality rates and autopsy findings

Medical Decision Making

Volumn 17, Issue 1, 1997, Pages 87-93

  Black, William C ^a,b   Nease Jr , Robert F ^c   Welch, H Gilbert ^a,d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA MEDICAL CENTER   (United States)

Author keywords

cohort studies; Markov process; population based mortality rates; precision; selection bias; stage distribution at autopsy; transition probabilities

Indexed keywords

ARTICLE; AUTOPSY; DISEASE COURSE; MORTALITY; PROBABILITY; PROGNOSIS; PROSTATE CANCER; STATISTICAL ANALYSIS; TIME OF DEATH;

ADULT; AGED; AGED, 80 AND OVER; AUTOPSY; CAUSE OF DEATH; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; MORTALITY; NEOPLASM STAGING; PROBABILITY; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 0031031888     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X9701700110     Document Type: Article

References (17)

1. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58.
2. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
3. Hennekens CH, Buring JE. 7. Cohort studies. In: Epidemiology in Medicine. Boston, MA: Little, Brown and Company, 1987;168-73.
4. Bruinvels DJ, Kievit J, Eijkemans RJC. Using age-specific rates in a Markov model (letter). Med Decis Making. 1993;13: 169.
5. Sonnenberg FA, Wong JB. Commentary: fine-tuning life expectancy calculations using Markov processes. Med Decis Making. 1993;13:170-2.
6. Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making. 1994;14:52-8.
7. Feuer EJ, Wun LM. DEVCAN: Probability of DEVeloping CANcer Software. Version 3.2. National Cancer Institute, 1995.
8. Mortality, part B. In: Vital Statistics in the United States. Annual ed. Hyattsville, MD: National Center for Health Statistics, 1986: vol 2.
9. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8:1-12.
10. Moolgavkar SH. The multi-stage theory of carcinogenesis and the age distribution of cancer in man. J Natl Cancer Inst. 1978;61:49-52.
11. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol. 1990;143:742-6.
12. Montie JE, Wood DP, Pontes E, et al. Adenocarcinoma of the prostate in cytoprostatectomy specimens removed for bladder cancer. Cancer. 1989;63:381-5.
13. Cowen ME, Chartrand M, Weitzel WF. A Markov model of the natural history of prostate cancer. J Clin Epidemiol. 1994; 47:3-21.
14. Morrison AS. 3. Early detection: sensitivity and lead time. In: Screening in Chronic Disease. 2nd ed. New York: Oxford University Press, 1992;57.
15. Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993;328:1237-43.
16. Feinstein AR, Esdaile JM. Incidence, prevalence, and evidence: scientific problems in epidemiologic statistics for the occurrence of cancer. Am J. Med. 1987;82:113-23.
17. Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med. 1980;303:130-5.